Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Olverembatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 69,387Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascentage Pharma Publishes Olverembatinib Phase Ib Data
    Ascentage Pharma Publishes Olverembatinib Phase Ib Data

    24 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/25/3193993/0/en/Ascentage-Pharma-Announces-Publication-of-Olverembatinib-Phase-Ib-Safety-Efficacy-and-Novel-Mechanism-Data-in-Gastrointestinal-Stromal-Tumors-in-Nature-s-Signal-Transduction-and-Ta.html

    GLOBENEWSWIRE
    24 Nov 2025
    Share Share
    Ascentage Pharma To Present Olverembatinib Data & POLARIS-1 Study
    Ascentage Pharma To Present Olverembatinib Data & POLARIS-1 Study

    03 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3179926/0/en/Ascentage-Pharma-to-Present-Data-from-Multiple-Studies-of-Olverembatinib-Including-the-First-Dataset-from-POLARIS-1-Study-at-ASH-2025.html

    GLOBENEWSWIRE
    03 Nov 2025
    Share Share
    EHA 2025: Olverembatinib Shows Encouraging Data in Ph+ ALL
    EHA 2025: Olverembatinib Shows Encouraging Data in Ph+ ALL

    15 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/15/3099530/0/en/EHA-2025-Multiple-Studies-Report-Encouraging-Data-of-Olverembatinib-in-Ph-ALL.html

    GLOBENEWSWIRE
    15 Jun 2025
    Share Share
    Ascentage Pharma's Assets to be Presented at 2025 EHA Congress
    Ascentage Pharma's Assets to be Presented at 2025 EHA Congress

    09 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/09/3096252/0/en/Thirteen-Studies-of-Ascentage-Pharma-s-Assets-Including-Olverembatinib-and-Lisaftoclax-Selected-for-Presentations-at-2025-European-Hematology-Association-Annual-Congress.html

    GLOBENEWSWIRE
    09 Jun 2025
    Share Share
    Ascentage Pharma Presents Preclinical Studies at 2025 AACR Meeting
    Ascentage Pharma Presents Preclinical Studies at 2025 AACR Meeting

    28 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/28/3069043/0/en/Ascentage-Pharma-Presents-Results-from-Five-Preclinical-Studies-at-2025-American-Association-of-Cancer-Research-AACR-Annual-Meeting-Highlighting-Strong-Synergistic-Effects-of-Olver.html

    GLOBENEWSWIRE
    28 Apr 2025
    Share Share
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO
    Ascentage Pharma Includes Lisaftoclax & Olverembatinib in CSCO

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/21/3064563/0/en/Ascentage-Pharma-Announces-Inclusion-of-Lisaftoclax-and-Olverembatinib-in-Chinese-Society-of-Clinical-Oncology-CSCO-2025-Guidelines.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share